Swipe om te navigeren naar een ander artikel
The aim was to investigate pain, skin sensations symptoms and patient self-reported, and parent proxy-reported cognitive functioning as predictors of generic health-related quality of life (HRQOL) in pediatric patients with Neurofibromatosis Type 1 (NF1) from the perspectives of patients and parents.
The Pain, Skin Itch Bother, Skin Sensations, and Cognitive Functioning Scales from the PedsQL™ Neurofibromatosis Type 1 Module and the PedsQL™ Generic Core Scales were completed in a multi-site national study by 323 patients and 335 parents. Patients were 5–25 years of age. Pain and skin symptoms and cognitive functioning were tested for bivariate and multivariate linear associations with generic HRQOL.
Pain, skin itch bother, skin sensations, and cognitive functioning were associated with decreased HRQOL in bivariate analyses (Ps < 0.001). In predictive analytics models, utilizing hierarchical multiple regression analyses controlling for demographic covariates, pain, skin itch bother, skin sensations, and cognitive functioning as a group accounted for 61 percent of the variance in patient-reported generic HRQOL (P < 0.001), reflecting a large effect size. For parent proxy-report, the predictor variables as a group accounted for 53% of the variance in generic HRQOL.
Pain, skin symptoms, and patient self-reported and parent proxy-reported cognitive functioning are key predictors of generic HRQOL in pediatric patients with NF1. Delineating NF1-specific symptoms and cognitive functioning as high-priority predictors from the patient and parents perspective enhances a family-centered approach in clinical research, clinical trials, and clinical practice intended to improve the global generic HRQOL of pediatric patients with NF1.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Monroe, C. L., Dahiya, S., & Gutmann, D. H. (2017). Dissecting clinical heterogeneity in Neurofibromatosis Type 1. Annual Review of Pathology, 12, 53–74. CrossRef
Blakeley, J. O., & Plotkin, S. R. (2016). Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro-Oncology, 18, 624–638. CrossRef
Vranceanu, A. M., Merker, V. L., Park, E. R., & Plotkin, S. R. (2015). Quality of life among children and adolescents with Neurofibromatosis 1: A systematic review of the literature. Journal of Neuro-Oncology, 122, 219–228. CrossRef
Nutakki, K., Hingtgen, C. M., Monahan, P., Varni, J. W., & Swigonski, N. L. (2013). Development of the adult PedsQL Neurofibromatosis Type 1 Module: Initial feasibility, reliability and validity. Health and Quality of Life Outcomes, 11, 21. CrossRef
Nutakki, K., Varni, J. W., Steinbrenner, S., Draucker, C. B., & Swigonski, N. L. (2017). Development of the Pediatric Quality of Life Inventory Neurofibromatosis Type 1 Module items for children, adolescents and young adults: Qualitative methods. Journal of Neuro-Oncology, 132, 135–143. CrossRef
Draucker, C. B., Nutakki, K., Varni, J. W., & Swigonski, N. L. (2017). The health-related quality of life of children, adolescents, and young adults with neurofibromatosis type 1 and their families: Analysis of narratives. Journal for Specialists in Pediatric Nursing, 22, e12174. CrossRef
Nutakki, K., Varni, J. W., & Swigonski, N. L. (2018). PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: Feasibility, reliability, and validity. Journal of Neuro-Oncology, 137, 337–347. CrossRef
Varni, J. W., Seid, M., & Kurtin, P. S. (2001). PedsQL™ 4.0: Reliability and validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in healthy and patient populations. Medical Care, 39, 800–812. CrossRef
Varni, J. W., & Limbers, C. A. (2009). The PedsQL™ 4.0 Generic Core Scales young adult version: Feasibility, reliability and validity in a university student population. Journal of Health Psychology, 14, 611–622. CrossRef
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale: Erlbaum.
Cohen, J., Cohen, P., West, S. G., & Aiken, L. S. (2003). Applied multiple regression/correlation analysis for the behavioral sciences (3rd ed.). Mahwah: Erlbaum.
Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. Psychometrika, 16, 297–334. CrossRef
Créange, A., Zeller, J., Rostaing-Rigattieri, S., Brugières, P., Degos, J. D., Revuz, J., & Wolkenstein, P. (1999). Neurological complications of neurofibromatosis type 1 in adulthood. Brain, 122, 473–481. CrossRef
DiMario, F. J., & Langshur, S. (2000). Headaches in patients with neurofibromatosis-1. Journal of Child Neurology, 15, 235–238. CrossRef
Bardo-Brouard, P., Luizard, C., Valeyrie-Allanore, L., Goujon, C., Do, B., Colin, A., Wolkenstein, P., & Paul, M. (2018). High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: A case series. Current Medical Research and Opinion, 34, 887–891. CrossRef
Brenaut, E., Nizery-Guermeur, C., Audebert-Bellanger, S., Ferkal, S., Wolkenstein, P., Misery, L., & Abasq-Thomas, C. (2016). Clinical characteristics of pruritus in neurofibromatosis 1. Acta Dermato-Venereologica, 96, 398–399. CrossRef
Khosrotehrani, K., Bastuji-Garin, S., Riccardi, V. M., Birch, P., Friedman, J. M., & Wolkenstein, P. (2005). Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients. American Journal of Medical Genetics Part A, 132A, 49–53. CrossRef
Ozonoff, S. (1999). Cognitive impairment in neurofibromatosis type 1. American Journal of Medical Genetics, 89, 45–52. CrossRef
Hyman, S. L., Shores, A., & North, K. N. (2005). The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology, 65, 1037–1044. CrossRef
Schwetye, K. E., & Gutmann, D. H. (2014). Cognitive and behavioral problems in children with neurofibromatosis type 1: Challenges and future directions. Expert Review of Neurotherapeutics, 14, 1139–1152. CrossRef
Payne, J. M., Hyman, S. L., Shores, E. A., & North, K. N. (2011). Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior. Child Neuropsychology, 17, 313–329. CrossRef
Varni, J. W., Limbers, C. A., & Burwinkle, T. M. (2007). Impaired health-related quality of life in children and adolescents with chronic conditions: A comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL™ 4.0 Generic Core Scales. Health and Quality of Life Outcomes, 5(43), 1–15. CrossRef
Nguyen, R., Kluwe, L., Fuensterer, C., Kentsch, M., Friedrich, R. E., & Mautner, V. F. (2011). Plexiform neurofibromas in children with neurofibromatosis type 1: Frequency and associated clinical deficits. Journal of Pediatrics, 159, 652–655. CrossRef
Varni, J. W., Limbers, C. A., & Newman, D. A. (2009). Using factor analysis to confirm the validity of children’s self-reported health-related quality of life across different modes of administration. Clinical Trials, 6, 185–195. CrossRef
Ater, J. L., Xia, C., Booth, M. M. C., Freyer, T. N., Packer, D. R., Sposto, R. J., Vezina, R., G., & Pollack, I. F. (2016). Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children’s Oncology Group. Cancer, 122, 1928–1936. CrossRef
- Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1
James W. Varni
Nancy L. Swigonski
- Springer International Publishing
Quality of Life Research
An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation - An Official Journal of the International Society of Quality of Life Research
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649